Taladegib(Taladegib) - 药物靶点：SMO_在研适应症：进行性纤维化间质性肺病，特发性肺纤维化_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Taladegib (USAN/INN)、ENV 101、ENV-IPF-101

+ [2]

靶点

SMO

作用方式

拮抗剂

作用机制

SMO拮抗剂(SMO受体拮抗剂)

治疗领域

呼吸系统疾病其他疾病

在研适应症

进行性纤维化间质性肺病特发性肺纤维化

非在研适应症

晚期癌症晚期恶性实体瘤广泛期小细胞肺癌+ [2]

原研机构

Eli Lilly & Co.

在研机构

Endeavor BioMedicines, Inc

非在研机构

Eli Lilly & Co.

权益机构

Ignyta, Inc.

Eli Lilly & Co.

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评孤儿药 (美国)、孤儿药 (欧盟)、优先药物（PRIME） (欧盟)

登录后查看时间轴

结构/序列

分子式C26H25ClF4N6O

InChIKeyZULPZIIPOBSSNQ-UHFFFAOYSA-N

CAS号1258861-21-0

关联

15

项与 Taladegib 相关的临床试验

NCT07454291

/ Recruiting临床1期

A Phase 1, Open-Label Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 in Healthy Participants

The purposes of this study are to:
1. evaluate potential interactions between taladegib (ENV-101) and current standard-of-care (SOC) therapies for idiopathic pulmonary fibrosis (IPF), including nintedanib and pirfenidone, and
2. more fully characterize the pharmacokinetics (PK) of taladegib (i.e., how the body absorbs, distributes, metabolizes and excretes taladegib).
This study will enroll 4 cohorts (groups) of participants. Each cohort will experience a different duration of treatment and sequestering (being housed) at the clinical site, followed by a 14-day follow-up period for safety evaluation. The longest duration of treatment for any cohort is 30 days.

开始日期2026-04-28

申办/合作机构

Endeavor BioMedicines, Inc

NCT06422884

/ Active, not recruiting临床2期

A Phase 2, Multi-Center, Randomized, Double-Blind, Controlled Trial Evaluating the Safety and Efficacy of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

The goal of this clinical trial is to evaluate the impact that ENV-101 has on lung function and key measures of fibrosis in adult patients with idiopathic pulmonary fibrosis (IPF). Another goal of this study is to better understand the safety and tolerability of ENV-101 in this patient population.

开始日期2024-11-15

申办/合作机构

Endeavor BioMedicines, Inc

NCT05817240

/ Completed临床1期

A Phase 1, Single-Center, Fixed Sequence, Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects

The goal of this clinical trial is to learn about the potential effect of ENV-101 (taladegib) on the pharmacokinetics of nintedanib (an approved treatment for idiopathic pulmonary fibrosis) when the two compounds are dosed together in healthy subjects. Participants in this study will receive ENV-101 and/or nintedanib on various days throughout a 10-day period during which they will reside at the clinical trial site.

开始日期2023-05-03

申办/合作机构

Endeavor BioMedicines, Inc

100 项与 Taladegib 相关的临床结果

登录后查看更多信息

100 项与 Taladegib 相关的转化医学

登录后查看更多信息

100 项与 Taladegib 相关的专利（医药）

登录后查看更多信息

36

项与 Taladegib 相关的文献（医药）

2026-06-01·INVESTIGATIONAL NEW DRUGS

Hedgehog Inhibitor and Paclitaxel: A Phase I Trial of the Oral Hedgehog inhibitor Taladegib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumours

Article

作者: Evans, T R Jeffry ; Blagden, Sarah Patricia ; Lewsley, Liz-Anne ; Brown, Jennifer ; Lockley, Michelle ; Thomson, Fiona ; Spiers, Laura ; Pou, Chantevy ; McNeish, Iain A ; McCartney, Elaine ; Glasspool, Rosalind ; Evans, Carol

Summary:

The hedgehog (Hh) signalling pathway is aberrantly activated in solid tumours. Inhibition of Hh signalling by SMO inhibitors is effective in the treatment of basal cell carcinomas and medulloblastomas whereas combination treatments may be required in other solid tumours. When given with an SMO inhibitor in preclinical models, the efficacy of paclitaxel is enhanced and there is potential reversal of mechanisms of resistance to paclitaxel supporting clinical investigation of the combination. In this phase I trial, the safety and feasibility of the oral SMO inhibitor, taladegib, was evaluated in combination with weekly paclitaxel in patients with advanced solid tumours. This was an open-label, nonrandomised, multicentre, dose escalation trial using a standard 3 + 3 design (EudraCT: 2014-004695-37 ISRCTN15903698). Primary objectives were to determine dose-limiting toxicities and the maximum tolerated dose of the combination. Patients received up to 6 cycles of paclitaxel 80 mg/m2 (day 1, 8 and 15 of a 28-day cycle). Then, 16 patients were recruited into 3 cohorts and received taladegib at 100 mg, 200 mg and 400 mg once daily, respectively. Grade 2/3 peripheral sensory neuropathy was the dose-limiting toxicity. The maximum tolerated dose of taladegib in combination with weekly paclitaxel was 200 mg once daily. Four patients had a partial response and 4 had confirmed stable disease at 16 weeks. The combination is feasible but cumulative neuropathy may limit longer term treatment. Hh signalling may be implicated in chemotherapy-induced neuropathy.

2025-11-01·Lancet Respiratory Medicine

Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial

Article

作者: Pitman, J ; Maher, T M ; Ramírez-Rivera, A ; Yu-Lin, A B ; de Los Rios, M ; Buendia-Roldan, I ; Perea, P C ; Goldin, J G ; Hobbs, B P ; Song, J W ; Thien, F ; DiFrancesco, A ; Hood, J

BACKGROUND:

The hedgehog (Hh) signalling pathway promotes fibrosis in idiopathic pulmonary fibrosis (IPF), an interstitial lung disease with a high mortality rate. Currently, there is no cure for IPF, and available anti-fibrotics only slow the rate of decline in lung function in IPF. We aimed to assess the safety and efficacy of taladegib (ENV-101), an Hh pathway inhibitor, in IPF in a phase 2a, proof-of-concept clinical trial.

METHODS:

ENV-IPF-101 was a randomised, double-blind, placebo-controlled, phase 2a trial conducted at 16 clinical sites in Australia, Canada, Malaysia, Mexico, and South Korea for patients with IPF older than 40 years who were not treated with concurrent IPF therapy. Patients were randomly assigned to taladegib 200 mg or placebo equivalent once daily, orally for 12 weeks, with a 6-week follow-up. The primary outcomes were safety in the intention-to-treat population and change from baseline in forced vital capacity (FVC) in the efficacy-evaluable population. Exploratory outcomes were measures of fibrosis on high-resolution CT (HRCT) in the efficacy-evaluable population. This study is registered with ClinicalTrials.gov, NCT04968574.

FINDINGS:

Between Aug 12, 2021, and July 28, 2023, 41 patients were randomly assigned to the taladegib group (n=21; three [14%] female and 18 [86%] male) or the placebo group (n=20; four [20%] female and 16 [80%] male). All treatment-emergent adverse events possibly or probably related to the study drug were grade 1 or 2, all except one were mild or moderate in severity, and none were serious adverse events. The most common treatment-emergent adverse events in the taladegib group were dysgeusia (12 [57%] of 21), muscle spasms (12 [57%] of 21), and alopecia (11 [52%] of 21); none of these events were reported in the placebo group, for which the most common adverse events reported were diarrhoea (four [20%] of 20), headache (three [15%] of 20), and dizziness (one [5%] of 20). Patients treated with taladegib had an improvement from baseline in FVC and across multiple HRCT-based measures of disease. Between-group differences in change from baseline to week 12 favoured taladegib for the efficacy measures of percent predicted FVC (3·95% [95% CI 0·31-7·60]; p=0·035; mean change from baseline of 1·9% in the taladegib group vs -1·3% for placebo), total lung capacity by HRCT (257·0 mL [95% CI 86·8-427·2]; p=0·0040; mean change from baseline of 206·67 mL in the taladegib group vs -55·58 mL in the placebo group), and percent quantitative interstitial lung disease (p=0·047; mean change from baseline of -9·4% in the taladegib group vs 1·1% in the placebo group). No deaths occurred during the trial.

INTERPRETATION:

The acceptable safety profile and efficacy analyses of taladegib support further investigation in a phase 2b trial in patients with IPF (WHISTLE-PF).

FUNDING:

Endeavor BioMedicines.

2025-09-14·Journal of Drug Targeting

Hedgehog signalling pathway inhibitors in the treatment of basal cell carcinoma: an updated review

Review

作者: Adela Markota Cagalj ; Zrinka Bukvic Mokos ; Ljiljana Serman ; Valentina Karin-Kujundzic ; Semir Vranic ; Alan Serman ; Lucija Skara Abramovic ; Mislav Glibo

Basal cell carcinoma (BCC) is the most common type of skin cancer that usually appears in sun-exposed body regions such as the head, trunk, and extremities. There are four main clinicopathological subtypes of BCC: nodular, superficial, morpheaform, and fibroepithelial. BCC's molecular basis includes inherited genetic susceptibility and somatic mutations, often induced by exposure to UV radiation. The aberrant activation of the hedgehog (Hh) signalling pathway, caused by mutations in the Hh components, plays a central role in the molecular pathogenesis of this carcinoma. This led to the development of Hh signalling pathway inhibitors as a new treatment option for patients with advanced disease. In this review, we summarise BCC's clinical presentation and histopathology and present knowledge on the most studied Hh signalling inhibitors, vismodegib and sonidegib, and other inhibitors of this signalling, such as itraconazole, patidegib, taladegib, and arsenic trioxide, in the treatment of BCC. We also present the most common Hh signalling inhibitor adverse events and their management options, which could improve patients' quality of life during treatment.

80

项与 Taladegib 相关的新闻（医药）

2026-10-14

·管线研发速递

重磅｜Taladegib IIb 期 WHISTLE-PF研究成功！首次显示IPF纤维化逆转潜力

导语特发性肺纤维化（IPF）是一种进展性、致死性的间质性肺病，现有治疗手段以延缓肺功能下降为主，很难实现肺纤维化逆转。近日，Endeavor BioMedicines 公布重磅临床数据：Hedgehog通路抑制剂Taladegib（ENV-101）的IIb期WHISTLE-PF全球多中心研究成功达到主要终点与多项关键次要终点，给药24周，不仅显著改善患者肺功能，HRCT影像指标也证实肺部纤维化得到改善，为IPF治疗赛道带来全新方向。 IPF临床痛点：只能“减速”，难以“逆转” 特发性肺纤维化病因不明，肺部会持续发生异常损伤修复，成纤维细胞过度活化，大量胶原沉积，肺组织慢慢变硬、失去弹性，患者呼吸困难进行性加重，中位生存期较短。目前全球已上市IPF药物作用定位为延缓肺功能衰退，可减慢疾病进展，但难以逆转已经形成的肺部纤维化。临床长期存在未被满足的需求：能否找到新靶点药物，不仅稳住肺功能，还能够减轻、逆转肺纤维化病灶。Taladegib正是瞄准这一缺口开发的小分子药物。药物机制：靶向Hedgehog通路，阻断纤维化根源 Taladegib（ENV-101）是一款Hedgehog（Hh）信号通路小分子抑制剂。在IPF病理进程中，Hedgehog通路异常激活，驱动上皮-间质转化，大量产生肌成纤维细胞，持续分泌基质蛋白，造成肺部瘢痕样纤维化。Taladegib通过抑制Hh通路关键受体，减少肌成纤维细胞生成，打断肺部过度异常的伤口重塑过程，理论上有望改善肺容积与肺功能，而不只是单纯减缓恶化。该药物此前已经获得FDA与欧盟的孤儿药资格认定，用于IPF治疗。 WHISTLE-PF IIb 期核心数据解读 WHISTLE-PF是一项全球多中心、随机、双盲、安慰剂对照IIb期剂量探索研究，评估Taladegib在IPF患者中24周治疗的疗效、安全性与耐受性。 ✅主要终点成功达成24周时，预计用力肺活量百分比（ppFVC）较基线变化，Taladegib 组相比安慰剂组具有统计学显著差异；药物组ppFVC较基线提升，直接证明药物可以改善肺功能，而非仅仅延缓下降。值得注意的是，一项针对患者持续治疗期间肺功能的预设分析显示，持续使用塔拉德吉布治疗，患者的预计用力肺活量百分比在24周内较基线水平持续改善。 ✅多项关键次要终点同时达标 1. FVC（mL）绝对值变化：Taladegib相比安慰剂展现出显著改善； 2. HRCT 定量纤维化影像指标：总肺容量TLC、定量间质性肺病占比% QILD、定量肺纤维化占比% QLF，药物组均较基线改善；24周影像证实肺部纤维化负荷下降，是本研究非常亮眼的结果。研究安全性数据将在后续学术会议公布。公司表示完整研究数据将在未来国际医学大会上正式披露。临床意义：IPF治疗范式潜在变革绝大多数IPF新药临床终点，目标是减少FVC下降速率；而本次WHISTLE-PF 研究中，Taladegib实现了肺功能指标上升+HRCT纤维化指标同步改善，代表药物有可能逆转肺部纤维化病变，这和现有抗纤维化药物的作用模式存在本质区别。 IIa 期数据已在《柳叶刀・呼吸病学》发表，IIb WHISTLE-PF 阳性结果进一步夯实概念验证。Endeavor BioMedicines 表示，本次肺功能、影像纤维化指标的统计学获益，验证 Hedgehog 通路作为 IPF 靶点的可行性，公司将继续推进后续开发计划，向 III 期研究迈进。公司官方观点：这一组兼具肺功能获益与影像纤维化减轻的数据，让 Taladegib 在 IPF 新药赛道中具备差异化优势，证实靶向 Hedgehog 通路治疗纤维化肺病的策略成立。小结与展望 IPF 新药研发失败率极高，全新靶点 IIb 期研究同时拿下主要 + 关键次要终点，是行业内值得关注的里程碑事件。Taladegib 开辟了 Hedgehog 通路抗纤维化的全新路径，如果 III 期能够重复本次阳性结果，有望改写 IPF 治疗格局，给患者带来逆转肺部纤维化的新选择。 ⚠️重要提示：Taladegib 目前仍处于临床试验阶段，尚未在任何国家获批上市，不可用于临床常规治疗。本内容仅为医药行业前沿资讯，不构成诊疗建议。

临床2期孤儿药临床结果

2026-10-14

·开拓药业

Endeavor IIb期治疗IPF临床结果喜人，Hedgehog信号通路靶点广受关注

Endeavor BioMedicines近日宣布，其IPF候选药taladegib（ENV-101）在IIb期研究中达到主要终点及多项关键次要终点。该结果凸显了taladegib在IPF治疗中的潜力，也进一步验证了靶向Hedgehog信号通路的策略。现有标准疗法尼达尼布和吡非尼酮仅能延缓肺功能下降，无法阻止或逆转病程。taladegib则通过抑制异常激活的Hedgehog通路，减少肺纤维化并改善肺功能。作为同靶点Hedgehog通路抑制剂，GT1708F同样具备治疗IPF潜力。其通过抑制SMO蛋白活性，影响Hh通路活性及下游相关蛋白表达。Hh通路再激活是IPF纤维化肺组织的特征，并影响纤维细胞迁移和增殖。特别指出的是，Hedgehog抑制剂不仅有望治疗IPF，在其他纤维化疾病中也具备开发价值。在体外研究中，GT1708F对Hh通路的抑制活性优于Taladegib。在体内IPF模型中，GT1708F能够有效改善肺纤维化，同剂量下优于taladegib。目前，GT1708F已完成治疗血液肿瘤的中国I期临床试验，并获许可开展治疗IPF的中国II期临床试验和美国I期临床试验。作为转型为皮肤外用领域的创新药大健康公司，我们对GT1708F在全球范围内的合作开发持开放态度，也期待与更多伙伴就权益授权等合作模式开展深入交流，包括但不限于License-out，成立newco等形式，希望携手合作伙伴，更快推进临床开发，让创新疗法早日惠及全球患者。关于开拓药业开拓药业成立于2009年，专注发展潜在“first-in-class”和“best-in-class”创新药物和功效性化妆品的研发及产业化，致力成为行业内的领军企业，并打造由外用创新药物研发业务、B2B功效性化妆品原料业务和B2C功效性化妆品产品业务共同组成的「三驾马车」商业模式。公司经过多年的发展，以皮科领域相关疾病为核心，研发多通道产品组合，产品覆盖全球高发病率疾病，并外延至功效性化妆品领域，可满足全球范围内的皮科临床需求及化妆品消费者需求。开拓药业前瞻性布局了包含小分子创新药及生物创新药的多元化产品管线，包括5款正在开展临床研究的产品以及多个正在进行临床前研究的项目。公司在全球拥有超百项已获得及申请中的专利。2020年5月22日，开拓药业正式在香港联合交易所有限公司主板挂牌上市，股票代码：9939.HK。欢迎访问公司网站：www.kintor.com.cn

2026-10-14

·开拓药业

Endeavor’s Phase IIb clinical for IPF met endpoint and the Hedgehog signaling pathway as a target drew widespread attention

Endeavor BioMedicines recently announced that its IPF candidate taladegib (ENV-101) met the primary endpoint and multiple key secondary endpoints in a Phase IIb study. These results highlight the potential of taladegib in the treatment of idiopathic pulmonary fibrosis (IPF) and further validate the strategy of targeting the Hedgehog (Hh) signaling pathway. Current standard-of-care therapies, nintedanib and pirfenidone, can only slow the decline in lung function and do not halt or reverse disease progression. Taladegib, by inhibiting aberrantly activated Hedgehog signaling, reduces pulmonary fibrosis and improves lung function. As a Hedgehog pathway inhibitor with the same target, GT1708F also has therapeutic potential for IPF. It inhibits SMO protein activity, thereby affecting Hh pathway activity and the expression of downstream related proteins. Hh pathway reactivation is a characteristic of fibrotic lung tissue in IPF and influences fibroblast migration and proliferation. Notably, Hedgehog inhibitors not only hold promise for the treatment of IPF but also have development value in other fibrotic diseases. In in vitro studies, GT1708F demonstrated superior inhibitory activity against the Hh pathway compared with taladegib. In in vivo IPF models, GT1708F effectively ameliorated pulmonary fibrosis and was superior to taladegib at the same dose. Currently, GT1708F has completed a phase I clinical trial in China for hematologic malignancies and has been authorized to initiate a phase II clinical trial in China and a phase I clinical trial in the US for IPF. As a great health company in innovative topical dermatological drugs, we are open to global collaborative development of GT1708F and look forward to in-depth discussions with more partners on collaboration models such as rights licensing, including but not limited to license-out and the formation of a NewCo. We hope to work together with partners to accelerate clinical development and bring innovative therapies to patients worldwide as soon as possible. About Kintor Pharmaceutical Limited Founded in 2009, Kintor Pharmaceutical Limited focuses on developing and commercializing potential "first-in-class" and "best-in-class" innovative drugs and functional cosmetics, aiming to be a leading enterprise in such areas, and establish a “troika” business model formed by R&D business of innovative topical drugs, B2B business of functional cosmetic raw materials and B2C business of functional cosmetic products. After several years' development, the Company has developed diverse product pipeline built on dermatology related diseases. The products cover diseases with high incidence rate globally and extend to functional cosmetics, which can meet the needs of clinical dermatology and cosmetics consumers worldwide. Kintor Pharma's layout includes innovative small molecule and biologic drugs, consisting of five productsunder clinical development and several preclinical research programs. Kintor Pharma has been granted more than 100 patents worldwide. On 22 May 2020, Kintor Pharma was officially listed on the Hong Kong Stock Exchange with the stock code 9939.HK. For more information, please visit www.kintor.com.cn.

临床结果临床研究引进/卖出临床1期

100 项与 Taladegib 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10671	-	-	DB12550

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
进行性纤维化间质性肺病	临床2期	阿根廷	Endeavor BioMedicines, Inc	2024-11-15
进行性纤维化间质性肺病	临床2期	澳大利亚	Endeavor BioMedicines, Inc	2024-11-15
进行性纤维化间质性肺病	临床2期	奥地利	Endeavor BioMedicines, Inc	2024-11-15
进行性纤维化间质性肺病	临床2期	比利时	Endeavor BioMedicines, Inc	2024-11-15
进行性纤维化间质性肺病	临床2期	加拿大	Endeavor BioMedicines, Inc	2024-11-15
进行性纤维化间质性肺病	临床2期	法国	Endeavor BioMedicines, Inc	2024-11-15
进行性纤维化间质性肺病	临床2期	德国	Endeavor BioMedicines, Inc	2024-11-15
进行性纤维化间质性肺病	临床2期	爱尔兰	Endeavor BioMedicines, Inc	2024-11-15
进行性纤维化间质性肺病	临床2期	意大利	Endeavor BioMedicines, Inc	2024-11-15
进行性纤维化间质性肺病	临床2期	马来西亚	Endeavor BioMedicines, Inc	2024-11-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04968574 (Company_Website) 人工标引	临床2期	特发性肺纤维化	-	ENV-101 (taladegib)	簾簾齋餘製繭廠範夢壓(鹽襯網製鑰積選構願獵) = 鹽網願鹹遞艱窪糧齋衊憲襯選壓襯鏇積觸築憲 (製餘鹽製糧窪鑰範衊構 ) 更多	积极	2025-05-20
				Placebo	簾簾齋餘製繭廠範夢壓(鹽襯網製鑰積選構願獵) = 窪窪觸憲艱遞夢網鏇積憲襯選壓襯鏇積觸築憲 (製餘鹽製糧窪鑰範衊構 ) 更多
NCT04968574 (ENV-IPF-101, ATS2025)	临床2期	特发性肺纤维化 lung volume \| vessel volume \| fibrosis extent ... 更多	34	ENV-101 200 mg	觸遞餘夢觸簾齋選糧觸(網餘簾淵鬱築遞衊範鏇) = 獵積壓遞餘艱網繭鏇遞蓋積鹹願遞鹹鑰積膚築 (觸鑰鏇構壓襯鑰淵積醖 ) 更多	积极	2025-05-16
				Placebo	觸遞餘夢觸簾齋選糧觸(網餘簾淵鬱築遞衊範鏇) = 選範製網築顧鏇齋襯齋蓋積鹹願遞鹹鑰積膚築 (觸鑰鏇構壓襯鑰淵積醖 ) 更多
NCT04968574 (ENV-IPF-101, ATS2024) 人工标引	临床2期	特发性肺纤维化	41	ENV-101	願蓋觸構糧蓋蓋夢鏇鹹(蓋鹽觸願選積願獵選簾) = The most common ENV-101-related adverse events were dysgeusia (alterations in taste; 57%), alopecia (52%) and muscle spasms (43%), which were all mild to moderate in severity. 繭範顧鬱選築夢鹽鏇鏇 (淵夢製齋醖壓鹹獵鹹鏇 ) 更多	积极	2024-05-19
ENV-101 (EADV2023)	临床2期	基底细胞癌 PTCH1 Loss of Function mutations	44	Taladegib 200 mg	憲顧選夢衊憲鏇築簾窪(窪襯齋簾鹽鑰齋顧夢鹽) = Patient reported alopecia during the study 範糧獵鑰夢簾鹹窪顧餘 (廠鑰鹹鑰範願製夢繭鏇 ) 更多	积极	2023-10-11
				Vismodegib
NCT02784795 (I6F-MC-JJCD, Pubmed \| Invest New Drugs)	临床1期	转移性实体瘤	63	Crenigacestat + Taladegib	築顧選糧夢遞蓋積鹹蓋(餘積鑰觸鬱鑰廠憲廠糧) = 鹽選憲觸壓網網鹽廠憲壓壓鹽鹹簾鏇簾壓憲築 (鹹獵鹹醖衊壓醖顧繭積 )	不佳	2021-03-08
				Crenigacestat + LY3023414	築顧選糧夢遞蓋積鹹蓋(餘積鑰觸鬱鑰廠憲廠糧) = 膚鏇觸繭選選蓋鬱願壓壓壓鹽鹹簾鏇簾壓憲築 (鹹獵鹹醖衊壓醖顧繭積 ) 更多
NCT01919398 (CTgov)	临床1期	晚期恶性实体瘤 \| 晚期癌症	19	LY2940680 (Cohort 1: 100 mg LY2940680)	繭淵鏇餘蓋觸憲鹹網範 = 鏇繭選顧壓鹽構糧簾餘願淵範壓齋鏇蓋構簾憲 (選廠製齋繭積衊鑰糧觸, 蓋顧鬱築蓋糧繭簾窪蓋 ~ 鹹夢繭醖觸廠製憲鑰範) 更多	-	2019-09-11
				LY2940680 (Cohort 2: 200 mg LY2940680)	繭淵鏇餘蓋觸憲鹹網範 = 壓鏇艱壓觸築憲構鑰範願淵範壓齋鏇蓋構簾憲 (選廠製齋繭積衊鑰糧觸, 鹽夢鬱製製襯選膚範網 ~ 膚襯糧蓋齋淵積餘願築) 更多
NCT01746745 (CTgov)	临床1期	-	6	[^14C]-LY2940680	鬱遞築夢憲範遞鑰獵蓋(壓壓糧鹽繭膚觸艱醖鏇) = 積構簾選壓衊鏇糧鹹製鑰鏇築積廠廠齋簾窪鹹 (窪窪選遞鏇憲鬱鬱鹹製, 2.81) 更多	-	2019-07-22
NCT01722292 (CTgov)	临床1/2期	广泛期小细胞肺癌	26	Etoposide+Carboplatin+LY2940680	廠鬱襯鏇繭廠膚顧製鬱(醖鬱簾獵夢艱鹽壓淵顧) = 襯繭壓壓膚艱衊鬱蓋醖襯齋願鹹憲醖餘糧顧顧 (簾簾獵膚範鑰遞壓範繭, 33) 更多	-	2018-12-28
NCT01919398 (Pubmed \| Invest New Drugs) 人工标引	临床1期	HR阳性/HER2低表达实体瘤	19	taladegib	積鏇夢壓顧夢顧觸壓網(構醖遞蓋憲糧遞憲簾鬱) = No dose-limiting toxicities (DLTs) were observed at doses of 100 mg or 200 mg; 3 of the 9 patients evaluable for DLTs at the 400 mg dose level experienced DLTs (thrombocytopenia: 1; decreased appetite: 2) 醖簾醖鏇艱艱積獵鏇衊 (顧鏇窪遞窪餘衊淵壓鬱 ) 更多	积极	2018-08-01
NCT01226485 (Pubmed \| Clin Cancer Res) 人工标引	临床1期	基底细胞癌 \| 晚期癌症	84	LY2940680	鏇鏇獵窪獵網淵範醖壓(繭膚觸觸壓襯選繭鹹淵) = 夢蓋壓獵鑰艱範構鏇鏇繭選鏇簾獵顧鹹襯願夢 (襯餘範遞簾顧遞鹹鏇憲 ) 更多	积极	2018-05-01